Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Thank you for registering! Take a moment to confirm your subscription to MarketBeat Daily Ratings so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.
Send Confirmation Email
NASDAQ:CNSP

CNS Pharmaceuticals (CNSP) Stock Price, News & Analysis

→ Global crypto currency reset (41 major banks signed up) (From Stansberry Research) (Ad)
Free CNSP Stock Alerts
$0.22
-0.01 (-3.51%)
(As of 05/17/2024 08:53 PM ET)
Compare
Today's Range
$0.21
▼
$0.24
50-Day Range
$0.19
▼
$0.43
52-Week Range
$0.19
▼
$2.98
Volume
197,800 shs
Average Volume
370,745 shs
Market Capitalization
$2.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media
CNSP stock logo

About CNS Pharmaceuticals Stock (NASDAQ:CNSP)

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

CNSP Stock Price History

CNSP Stock News Headlines

May 16, 2024 | investorplace.com
CNSP Stock Earnings: CNS Pharmaceuticals Reported Results for Q1 2024
May 16, 2024 | finanznachrichten.de
CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports First Quarter 2024 Financial Results
May 13, 2024 | americanbankingnews.com
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Short Interest Up 35.1% in April
April 25, 2024 | theglobeandmail.com
CNS Pharmaceuticals (NASDAQ: CNSP) CEO to Present at LSX World Congress 2024
April 4, 2024 | theglobeandmail.com
CNS Pharmaceuticals (NASDAQ: CNSP) Releases FY 2023 Financial Report, Corporate Update
April 3, 2024 | benzinga.com
CNS Pharma Stock (NASDAQ:CNSP), Earnings Estimates, EPS, and Revenue
April 2, 2024 | investorplace.com
CNSP Stock Earnings: CNS Pharmaceuticals Reported Results for Q4 2023
March 20, 2024 | theglobeandmail.com
CNS Pharmaceuticals (NASDAQ: CNSP) Welcomes Proven Commercialization Leader to Board
February 9, 2024 | investing.com
Cns Pharmaceuticals Inc (CNSP)
February 3, 2024 | msn.com
CNS Pharmaceuticals Launches Public Offering for Trial Funding
January 30, 2024 | theglobeandmail.com
CNS Pharmaceuticals (NASDAQ: CNSP) Releases Info on $4M Public Offering Pricing
January 29, 2024 | finanznachrichten.de
CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering
January 29, 2024 | finance.yahoo.com
CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering
January 19, 2024 | theglobeandmail.com
CNS Pharmaceuticals (NASDAQ: CNSP) Names Seasoned Biotech Leader to Board of Directors
January 18, 2024 | finanznachrichten.de
CNS Pharmaceuticals, Inc.: Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors
January 18, 2024 | finance.yahoo.com
Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors
January 17, 2024 | finance.yahoo.com
CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
January 6, 2024 | seekingalpha.com
CNSP CNS Pharmaceuticals, Inc.
December 18, 2023 | finance.yahoo.com
CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin
December 14, 2023 | morningstar.com
CNS Pharmaceuticals Inc Ordinary Shares
December 8, 2023 | msn.com
CNS Pharmaceuticals files to sell 3.81M shares of common stock
December 6, 2023 | finance.yahoo.com
How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure
November 22, 2023 | finance.yahoo.com
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy
November 21, 2023 | msn.com
CNS Pharmaceuticals files to sell 3.76M shares of common stock for holders
November 16, 2023 | finance.yahoo.com
CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate
See More Headlines

Company Calendar

Last Earnings
4/01/2024
Today
5/19/2024
Next Earnings (Estimated)
8/12/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CNSP
CUSIP
N/A
CIK
1729427
Web
www.cnspharma.com
Phone
800-946-9185
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($3.48)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-18,850,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-603.40%
Return on Assets
-575.33%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.26
Quick Ratio
0.26

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.37) per share
Price / Book
-0.59

Miscellaneous

Outstanding Shares
11,850,000
Free Float
10,762,000
Market Cap
$2.57 million
Optionable
Not Optionable
Beta
2.78

CNSP Stock Analysis - Frequently Asked Questions

How have CNSP shares performed in 2024?

CNS Pharmaceuticals' stock was trading at $1.27 at the beginning of the year. Since then, CNSP stock has decreased by 82.9% and is now trading at $0.2170.
View the best growth stocks for 2024 here.

When is CNS Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024.
View our CNSP earnings forecast.

How were CNS Pharmaceuticals' earnings last quarter?

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) announced its quarterly earnings data on Monday, April, 1st. The company reported ($0.95) earnings per share for the quarter.

When did CNS Pharmaceuticals' stock split?

Shares of CNS Pharmaceuticals reverse split on Tuesday, November 29th 2022. The 1-30 reverse split was announced on Tuesday, November 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of CNS Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CNS Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), Advanced Micro Devices (AMD), Heat Biologics (HTBX), Roku (ROKU), Aldeyra Therapeutics (ALDX), Salesforce (CRM), Gilead Sciences (GILD), Inseego (INSG), Nokia Oyj (NOK) and Block (SQ).

When did CNS Pharmaceuticals IPO?

CNS Pharmaceuticals (CNSP) raised $9 million in an IPO on Friday, November 8th 2019. The company issued 2,100,000 shares at a price of $4.00-$5.00 per share. Benchmark served as the underwriter for the IPO.

How do I buy shares of CNS Pharmaceuticals?

Shares of CNSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CNSP) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners
Urgent Nvidia Warning
Altimetry
The Overlooked Retirement Asset You Probably Don’t Own
Crypto 101 Media
Shocking: One AI startup's revenue could surge 4,735%
Manward Press
"The Biggest Drug Ever" Is Coming
Behind the Markets
Exposed: 10 CENT Crypto to Explode May 20th?
True Market Insiders
CEO of Biggest AI Chipmaker Just Dropped a Bombshell…
Banyan Hill Publishing
Elon’s New Device is About to Shock the World
InvestorPlace
Most important medical advance in 100 years
The Oxford Club